Fig. 1: Overview of current treatment options and future directions in the early RRMM treatment landscape. | Blood Cancer Journal

Fig. 1: Overview of current treatment options and future directions in the early RRMM treatment landscape.

From: Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy

Fig. 1

The agents commonly used for treatment of patients with multiple myeloma in frontline and early relapsed/refractory settings are presented on the left (Current Treatments); agents being evaluated in clinical trials or entering the treatment space are described on the right (Future Directions). ADC antibody-drug conjugate, BCMA B-cell maturation antigen, CAR chimeric antigen receptor, CELMoD cereblon E3 ligase modulating drug, FcRH5 Fc receptor-homolog 5, GPRC5D G-protein coupled receptor family C group 5, mAb monoclonal antibody, MM multiple myeloma, RRMM relapsed/refractory multiple myeloma, SLAMF7 SLAM family member 7.

Back to article page